(Reuters) – Germany-based CureVac NV said on Tuesday it had partnered with Swiss contract manufacturer Celonic Group to produce more than 100 million doses of its COVID-19 vaccine candidate.
The vaccine, CVnCoV, will be produced at Celonic’s facility in Heidelberg, Germany.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)
